Received Jul 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | P7FJ2 | — |
adult female patient received Arexvy adjuvant alone without the powder; adult female patient received Arexvy adjuvant alone without the powder; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 81-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number P7FJ2, expiry date 30-NOV-2025) for prophylaxis. On 28-JUN-2025, the patient received Arexvy. On 28-JUN-2025, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: adult female patient received Arexvy adjuvant alone without the powder) and inappropriate dose of vaccine administered (Verbatim: adult female patient received Arexvy adjuvant alone without the powder). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 30-JUN-2025 Clinical director wanted to see if they need to revaccinate because the patient received Arexvy adjuvant alone without the powder, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The vaccine administration facility was the same as primary reporter.